Introduction {#s1}
============

Dendritic cells (DC) are a specialized professional antigen presenting cells (APC) with unique capability to initiate and maintain primary immune responses when pulsed with antigens ([@B1]--[@B3]). Following recognition of pathogen- or damage-associated molecular patterns (PAMPs or DAMPs, respectively) by innate pattern recognition receptors (PRRs), DC activate and turn into a potent APC. The final differentiation of activated DC is characterized by plasma membrane up-regulation of MHC-II and co-stimulatory molecules (i.e., CD86, CD80), and the production of cytokines important for T CD4^+^ lymphocytes activation at the immunologic synapsis (i.e., IL-12 and IL-18; and/or IL-1ß; or IL-4). The result of DC activation drives the polarization of T CD4^+^ lymphocytes, and therefore of the immune response ([@B4]).

Successful vaccine preparations have to properly activate DC to induce a long-term memory protective immunity. Together with pathogen\' antigens, adjuvants strongly contribute to the effectiveness of a vaccine. Their action is mediated by DC PRRs, such as Toll-like receptors (TLRs) and NACHT and LRR containing receptors (NLRs), through the activation of intracellular pathways leading to the production of cytokines important for T cell activation ([@B5]). Alum (aluminum hydroxide), a commonly used adjuvant, activates murine DC through the induction of the NLR-containing a PYD domain 3 (NLRP3) and the consequent mounting of the cytoplasmic complex, known as inflammasome, which results in caspase-1 activation and IL-1ß and IL-18 production. The absence of NLRP3 results in the loss of adjuvant responsivity ([@B6]), emphasizing the central role of inflammasome in the activation of DC and in the induction of an efficient immune response.

Accordingly, recent findings have reported that individuals with a low response to vaccines, such infants ([@B7]) or cancer patients ([@B8]) present a substantial alteration in inflammasome expression and/or activity.

Immune response to many current vaccines is known to be impaired and/or less effective in chronically HIV-infected individuals ([@B9]). This impairment has been associated to both a reduced frequency of DC ([@B10], [@B11]), together with phenotypic and functional alterations of these cells ([@B12]). As HIV-infected patients present well-documented DC impairment, it has been proposed that a poor response to vaccination could be caused by a diminished and/or defective response to common adjuvants ([@B13]).

We have previously demonstrated that NLRP3 inflammasome is not correctly activated by bacterial lipopolysaccharide (LPS) in monocyte-derived dendritic cells (MDDC) from HIV-infected patients (HIV-DC) ([@B14]), possibly as a result of the HIV-associated chronic inflammation and the consequent immune system exhaustion ([@B15]). As NLRP3 inflammasome is involved in the activation of DC by vaccine adjuvants ([@B6], [@B16]), the defect observed in NLRP3 inflammasome possibly contributes to the less extend immunization response in HIV-infected individuals.

To counteract the low immune response, new vaccination strategies have been proposed, such as the use of PRRs agonists, such as LPS or flagellin (FLG), as largely reviewed in ([@B17]).

FLG is the main component of a bacterial flagellum, and it is recognized extracellularly by TLR5 inducing a Myd88 signaling and promoting the transcription of NF-κB-related genes ([@B18], [@B19]); and by the intracellular receptors, NLR-containing a BIR domain (NAIP) and NLR-containing a CARD domain (NLRC)-4. NAIP directly binds FLG, while NLRC4 recognizes the NAIP:FLG complex and mounts the NAIP/NLRC4 inflammasome, resulting in IL-1ß and IL-18 production ([@B20]--[@B22]).

FLG has already been used as an adjuvant in a number of clinical trials of healthy individuals ([@B23], [@B24]), however to our knowledge none or poor data are available about its ability to activate MDDC in both healthy or immuno-compromised individuals via NAIP/NLRC4 inflammasome.

Taking in account the key role of the inflammasome in proper DC activation, and the impairment of NLRP3 activation observed in HIV-DC, we hypothesize that FLG could represent an alternative adjuvant for HIV-infected patients, by activating inflammasome in DC through NAIP and NLRC4 receptors, and in this way by-passing the NLRP3 defect. Therefore, the aim of this study was to demonstrate that FLG is able to activate MDDC from HIV-infected individuals better than LPS, and to what extent the entity of inflammasome activation differs between HIV-DC and HD-DC.

Materials and Methods {#s2}
=====================

HIV-Infected Patients
---------------------

Twenty-seven HIV-infected adults patients (16 males/11 females; 51.9 ± 11.7 years), proceeding from the metropolitan area of São Paulo (SP, Brazil), seropositive for at least 5 years (26.9 ± 16.9 years), in antiretroviral therapy (ART), with blood CD4^+^ T cells count \>500 cells/μl, without clinical AIDS or other chronic diseases (i.e., neoplasias, cardiovascular disease, autoimmune disease, kidney disease, obesity) or infectious diseases (i.e., human T-lymphotropic virus/HTLV, hepatitis B or hepatitis C virus), were recruited from January 2016 to May 2018 at the "Serviço de Extensão ao Atendimento de Pacientes HIV/AIDS" (SEAP) of the Faculty of Medicine, University of São Paulo (São Paulo, SP, Brazil). Fifty milliliter of the peripheral blood was collected in heparin tubes. All volunteers assigned the informed consent approved by the Institutional Ethical Committee. Patients\' main characteristics are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Main characteristics of healthy donors and HIV-infected patients.

                                                                        **HD (*n* = 27)**   **HIV (*n* = 27)**
  --------------------------------------------------------------------- ------------------- --------------------
  Gender (M/F), n                                                       15/12               16/11
  Age (years), mean ± SD                                                45.5 ± 13.4         51.9 ± 11.7
  Time from diagnosis (years), mean ± SD                                                    26.9 ± 16.9
  PVL[^\*^](#TN1){ref-type="table-fn"} (log RNA copies/μL), mean ± SD                       1.77 ± 0.37
  PVL[^0^](#TN2){ref-type="table-fn"} (log RNA copies/μL), mean ± SD                        4.00 ± 1.02
  PVL[^1^](#TN3){ref-type="table-fn"} (log RNA copies/μL), mean ± SD                        2.25 ± 0.77
  CD4^+^ T[^\*^](#TN1){ref-type="table-fn"} (cells/μL), mean ± SD                           768.9 ± 283.1
  CD4^+^ T[^0^](#TN2){ref-type="table-fn"} (cells/μL), mean ± SD                            377.5 ± 389.9
  CD4^+^ T[^1^](#TN3){ref-type="table-fn"} (cells/μL), mean ± SD                            679.0 ± 252.7

Gender and age are reported for healthy donors (HD) and HIV-infected patients (HIV). Time from HIV-1 diagnosis as well as plasma viral load (PVL) and CD4^+^ T cells counts at the time of blood collection

, before

and after

*the start of anti-retroviral therapy (ART) were included for HIV-infected patients. The detection limit of PVL was 1.70 log HIV-1 RNA copies/ml. M, males; F, females; n, number of individuals; SD, standard deviation*.

Healthy Donors (HD)
-------------------

Twenty-seven adults (15 males/12 females; 45.5 ± 13.4 years), proceeding from the metropolitan area of São Paulo (SP, Brazil), without clinical HIV or other chronic or infectious diseases, were recruited at the Blood Bank Service of the Hospital "Oswaldo Cruz" (São Paulo, SP, Brazil). Fifty milliliter of the peripheral blood was collected in heparin tubes. All volunteers assigned the informed consent approved by the Hospital Ethical Committee. HD demographic data were included in [Table 1](#T1){ref-type="table"}. Of note, any significant difference exists in gender ratio (Fisher test *p* \> 0.05) or age mean value (*t*- test *p* \> 0.05) between HD and HIV-infected patients.

Human Monocyte-Derived Dendritic Cells (MDDC)
---------------------------------------------

Mononuclear cells were isolated from 50 mL of peripheral blood by Ficoll-Hypaque (GE Healthcare) density gradient, and monocytes were separated from lymphocytes by plastic adherence. Briefly, 4 × 10^6^ mononuclear cells/well were incubated in 24-wells culture plates (Corning-Costar). After 2 h, non-adherent cells (mainly lymphocytes) were removed and cryopreserved at −80°C for co-culture assays, while adherent cells (mainly monocytes) were cultured with 50 ng/mL GM-CSF (Peprotech) and 50 ng/mL IL-4 (Peprotech) in RPMI-1640 (Gibco, Thermo Fisher Scientific) supplemented with 10% of fetal bovine serum (FBS; Gibco) at 37°C in 5% CO~2~ for 5 days ([@B25]). Monocytes-to-DC differentiation was confirmed by flow cytometry analysis of CD14 and CD11c surface markers ([Supplementary File 1](#SM1){ref-type="supplementary-material"}).

MDDC (HIV-DC or HD-DC) were stimulated with purified 5 μg/mL FLG from S. *typhimurium* (FLA-ST, Invivogen) or 1 μg/mL LPS from E. *coli* (Sigma-Aldrich, Merck) for 3, 8, 18, and 24 h and 1 mM ATP was added for more 15 min ([@B26]). In some experiments, MDDC were pre-incubated with 10 μg/mL MCC-950 (Invivogen), a specific NLRP3 inhibitor ([@B27]), or 10 μM parthenolide (PTD; Sigma-Aldrich, Merck), a NF-κB and caspases inhibitor ([@B28]); or with 1,000 UI/mL IFN-α-2b (Schering-Plough) for 18 h ([@B29], [@B30]). Cell supernatants were collected for cytokines measurement. MDDC were used for cytometric assays or RNA isolation and genes expression analysis.

To assess MDDC ability to activate CD4^+^ T lymphocytes, 0.4 × 10^5^ MDDC were distributed in 96-well U-bottom suspension culture plates with 4.0 × 10^5^ autologous lymphocytes (cryopreserved non-adherent peripheral blood mononuclear cells) (co-culture MDDC/lymphocytes ratio: 1/10) in duplicates and cultured in the presence of unspecific (not antigen-specific) stimuli for 96 or 120 h to measure IFN-γ production and lymphocytes proliferation, respectively. Lymphocytes alone were used as a negative control (Neg).

MDDC Phenotype Analysis
-----------------------

2 × 10^5^ DC/mL were incubated in Phosphate Buffer Saline (PBS; Sigma-Aldrich, Merck) with the optimal dilution of anti-CD14 PE (MEM15; Exbio), anti-CD11c (3.9; Biolegend), anti-HLA-DR V500 (G46-6; BD Biosciences), anti-CD86 PE-cy7 (2331/FUN-1, B), and anti-CD40 Horizon 450 (5C3; BD Biosciences) antibodies for 20 min at 4°C. Cells were then washed twice with PBS and resuspended in 200 μL of 4% Formaldehyde-PBS. The Live/Dead Fixable Cell Stain Kit (Life Technology, Thermo Fisher Scientific) was added to the assay according to the manufacturer\'s instructions. A minimum of 50,000 events was acquired on a LSRFortessa™ X-20 flow cytometer (BD Biosciences) using the FACS Diva software (BD Biosciences). Data were analyzed using the FlowJo software (Tree Star). The gates strategy for one representative experiment was reported in [Supplementary File 2](#SM1){ref-type="supplementary-material"}.

CD4^+^ T Lymphocytes Activation Assay
-------------------------------------

CD4^+^ T lymphocytes activation was measured by the meaning of intracellular staining of IFN-γ. Briefly, autologous co-cultures of MDDC and lymphocytes were treated with lymphocyte mitogens Ionomycin (1 μg/mL; Sigma-Aldrich, Merck) and Phorbol Myristate Acetate (10 ng/mL; Sigma-Aldrich, Merck) for 96 h ([@B31]). Twenty microgram per milliliter Brefeldin A (Sigma-Aldrich, Merck) was added 6 h before the end of co-culture to block Golgi secretory pathway. Cells were then labeled for surface marker anti-CD3 APC (MEM-57) and anti-CD4 PE (RPAT4) (BD Biosciences), permeabilized with Cytofix/Cytoperm solution (BD Biosciences), and finally stained for anti-IFN-γ V450 (B27; BD Biosciences). The Live/Dead Fixable Cell Stain Kit was added to the assay according to the manufacturer\'s instructions. Cells were then washed twice with PBS and resuspended in 200 μL of 4% Formaldehyde-PBS to proceed to flow cytometry analysis as above-mentioned.

CD4^+^ T Lymphocytes Proliferation Assay
----------------------------------------

The CFSE Cell Division Tracker Kit (Biolegend) was used for flow cytometry analysis of *in vitro* CD4^+^ T cells proliferation assay according to manufacturers\' protocol. Briefly, autologous lymphocytes were pre-treated with 0.1 μM CFSE before being added to MDDC cultures in the presence of the lymphocyte mitogen Concanavalin A (5 μg/mL; Sigma Aldrich, Merck) for 120 h ([@B32]). At the end of assay, cells were then labeled for anti-CD3 APC (MEM-57) and anti-CD4 PE (RPAT4) (BD Biosciences). The Live/Dead Fixable Cell Stain Kit was added to the assay according to the manufacturer\'s instructions. Cells were then washed twice with PBS and resuspended in 200 μL of 4% Formaldehyde-PBS to proceed to flow cytometry analysis as above-mentioned.

Cytokines Measurement in Culture Supernatants
---------------------------------------------

IL-1β, IL-18, TNF-α, and IL-12p70 were measured in MDDC culture supernatants by ELISA according to the manufacturers\' protocols (Biolegend for IL-1β; IL-18, TNF; eBioscience for IL12p70). Data were reported as pg/mL.

Caspase-1 Activity Assay
------------------------

The detection of caspase-1 activity in MDDC was measured with the FAM FLICA Caspase-1 Assay Kit (Immunochemistry Technologies) and flow cytometry according to the manufacturer\'s protocol. Briefly, 10 μL 30x FLICA was added to 2 × 10^5^ MDDC in 300 mL and cells incubated for 1 h at 37°C 5% CO~2.~ The Live/Dead Fixable Cell Stain Kit was used. Cells were then washed twice with PBS and resuspended in 200 μL of 4% Formaldehyde-PBS to proceed to flow cytometer analysis as above-mentioned. Live MDDC were gated based on their forward (FSC) and side light scatter (SSC). Histograms for one representative experiment was reported in [Supplementary File 3](#SM1){ref-type="supplementary-material"}.

Inflammasome Genes Expression Analysis
--------------------------------------

Total RNA was isolated from 2 × 10^5^ MDDC using the RNAqueous-Micro kit (Ambion, Thermo Fisher Scientific) according to manufacturer\'s protocol and quantified using Nanodrop N-1000 (Agilent). 0.5 μg of total RNA was converted into cDNA using Superscript III RT kit and random primers (Invitrogen, Thermo Fisher Scientific). *NLRP1* (hs00248187), *NLRP3* (hs00366465), *NAIP* (hs03037952), *NLRC4* (hs00368367), *CASP1* (hs00354836), *IL1B* (hs01555410), *IL18* (hs01038788), *CARD8* (hs01088221), *BRCC3* (hs02386484), and *NEDD8* (hs01921826) genes were amplified using TaqMan® gene-specific assays (Applied Biosystems, Thermo Fisher Scientific) and qPCR on the QuantStudio 3.0 Real-Time PCR equipment (Applied Biosystems, Thermo Fisher Scientific). The QuantStudio 3.0 software was used to obtain cycle threshold values (Ct) for relative gene expression analysis according to Fold Change (FC) method ([@B33]). Raw expression data (Ct) were normalized with the expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase/*GAPDH* (hs02758991; TaqMan® assay) (ΔCt), and the FC was calculated comparing stimulated and unstimulated (UN) conditions (FC = 2^−ΔΔ*Ct*^; ΔΔCt = ΔCt~stimulated~-ΔCt~UN~). Alternatively, the basal (constitutive) gene expression was calculated as 2^−Δ*Ct*^.

miR-223 Expression Analysis
---------------------------

Total RNA was isolated from 2 × 10^5^ MDDC by mirVana™ miRNA Isolation Kit (Ambion, Thermo Fisher Scientific) according to the manufacturer\'s instructions. 0.5 μg of total RNA were converted into cDNA using kit TaqMan™ MicroRNA Reverse Transcription and miRNA-specific primers (Applied Biosystems, Thermo Fisher Scientific). miR-223 was amplified using TaqMan® miR-specific assays (*TM:002098*; Applied Biosystems, Thermo Fisher Scientific) and qPCR on the QuantStudio 3.0 Real-Time PCR equipment. The QuantStudio 3.0 software was used to obtain cycle threshold values (Ct) for relative gene expression analysis according to Fold Change (FC) method ([@B33]). Raw expression data (Ct) were normalized with the expression of and non-coding small RNA control U6 (*TM:001973*; TaqMan® assay) (ΔCt), and the FC was calculated comparing stimulated and unstimulated (UN) conditions (FC = 2^−ΔΔ*Ct*^; ΔΔCt = ΔCt~stimulated~-ΔCt~UN~). Alternatively, the basal (constitutive) gene expression was calculated as 2^−Δ*Ct*^.

Detection of "Specks" Formation
-------------------------------

Detection of inflammasome "specks" formation was performed by confocal microscopy and immunofluorescence, as previously described ([@B34]). Briefly, 2 × 10^5^ MDDC were cultured in 16-wells chamber slides (Thermo Fisher Scientific) and stimulated with 5 μg/mL FLG or 1 μg/mL LPS for 24 h at 37°C 5% CO~2~ with or without 1 mM ATP. Cells were then fixed and permeabilized with Cytofix/Cytoperm reagent (BD Biosciences) for 30 min at 37°C 5% CO~2~, and incubated with primary antibody for NLRP3 (1:100 mouse anti-human NLRP3, Abcam) and/or NLRC4 (1:200 rabbit anti-human NLRC4; Biolegend) overnight at room temperature. Fluorescent secondary antibodies (Alexa 488-conjugated goat-anti-mouse IgG1, or Alexa 647-conjugated goat-anti-rabbit IgG1; Biolegend) were then added for 1 h. Finally, cells were washed and fixed to image acquisition at DMi8 confocal laser scanning microscope (Leica). 4′,6-Diamidine-2′-phenylindole dihydrochloride (DAPI; Sigma-Aldrich, Merck) was used for nuclear counterstaining. ImageJ software and related plugins (National Institutes of Health) were used for image processing. The counting of NLRP3+ and NLRC4+ specks in MDDC was performed manually by observing specks formation within the cells ([@B34]), and through the ImageJ software by calculating the corrected total cellular fluorescence (CTCF) for each marker as integrated density--(area of selected cell × mean fluorescence of background readings) ([@B35]).

*NLRC4* and *NLRP3* Silencing
-----------------------------

Pre-validated shRNA for human *NLRC4* and *NLRP3* was obtained from MISSION® shRNA Plasmid DNA (Sigma-Aldrich, Merck). The shRNAs for NLRP3 and NLRC4 used in the study are listed in [Supplementary File 4](#SM1){ref-type="supplementary-material"}. 2 × 10^5^ MDDC were transduced using with the same amounts of lentiviral particles encoding non-targeting control or gene-specific shRNA in the presence of SIV3+ VLP for 48 h. Thereafter, cells were treated with 5 μg/mL FLG or 1 μg/mL LPS for 24 h. The shRNA knockdown efficiency of the target protein in lentivirus-transduced cells was assessed by gene expression ([Supplementary File 5](#SM1){ref-type="supplementary-material"}). The concentrations of IL-1β in cell culture supernatants was measured by ELISA.

Data Analysis
-------------

All data were collected and analyzed from at least three independent experiments. Normality test was applied to the data, and parametric or non-parametric analysis was used accordingly to compare two or more data sets as specified for each graph. The level of significance was *p* \< 0.05. Calculations were performed using the statistical software package GraphPad Prism 7.0.

Biosecurity and Institutional Safety Procedures
-----------------------------------------------

All research was performed following the guidelines of biosecurity and safety of Institute of Biomedical Science (ICB/USP).

Results {#s3}
=======

Flagellin Similarly Activates MDDC From HIV-Infected Patients and Healthy Donors
--------------------------------------------------------------------------------

MDDC were treated with 5 μg/mL FLG for 24 h and phenotypic profile, TNF and IL-12 secretion as well as CD4^+^ T lymphocytes activation in co-culture experiments were assessed based on previously published protocols ([@B31], [@B32]).

FLG activates MDDC, both HIV-DC and HD-DC, as indicated by the increase of co-stimulatory molecules, cytokines release and CD4^+^ T lymphocytes activation ([Figure 1](#F1){ref-type="fig"}).

![Flagellin similarly activates HIV-DC and HD-DC. 2 × 10^5^ MDDC from healthy donors (HD-DC; *n* = 5) and HIV-infected patients (HIV-DC; *n* = 5) were stimulated with 5 μg/ml flagellin (FLG) for 24 hours. Viability, expression of characteristic DC surface markers **(A)** as well as TNF **(B)** and IL-12p70 **(C)** secretion were analyzed and compared between untreated (UN) and stimulated (FLG) conditions as well between HD-DC and HIV-DC groups 0.4 × 10^5^ FLG-treated MDDC were cultured with 4 × 10^5^ autologous lymphocytes (MDDC/lymphocytes ratio: 1/0) for 96 hours to detect IFN-γ production in CD4^+^ T lymphocytes (percentage of CD3^+^ CD4^+^ T IFN-γ^+^ cells) **(D)**, or 120 hours to measure CD4^+^ T lymphocytes proliferation (percentage of CD3^+^ CD4^+^ T CSFE^low^ cells) **(E)**. Lymphocytes alone were used as a negative control (Neg). Data are reported as mean ± standard error. Multiple *t*-test **(A)** and Two-Way ANOVA test **(B--E)** were applied to compare conditions within a group (HIV-DC or HD-DC; ^\*^*p* \< 0.05) and between groups (HIV-DC vs. HD-DC; ^§^*p* \< 0.05).](fimmu-10-01291-g0001){#F1}

As expected, FLG induced the up-regulation of HLA-DR (95.83 ± 0.68 % positive cells) compared to untreated cells (UN: 77.5 ± 4.4 % positive cells) and the significant increase of CD40 (FLG: 39.8 ± 3.7 %, vs. UN: 7.8 ± 2.0 % positive cells; *p* = 3 × 10^−5^) in HD-DC, but not of CD86, which appeared to be decreased in HD-DC+FLG compared to untreated cells (FLG: 62.8 ± 4.3 %, vs. UN: 91.1 ± 2.9 % positive cells; *p* = 0.001) ([Figure 1A](#F1){ref-type="fig"}). However, this result could be due to a previously reported positive feedback mechanism and not to a negative effect of FLG ([@B36]). A significant augment of HLA-DR (FLG: 83.5 ± 6.1 %, vs. UN: 49.2 ± 9.5 % positive cells; *p* = 0.006) and CD40 (FLG: 48.7 ± 5.4 %, vs. UN: 17.4 ± 1.7 % positive cells; *p* = 0.020) was observed in HIV-DC challenged with FLG. The expression of CD86 did not change in treated or untreated cells ([Figure 1A](#F1){ref-type="fig"}).

It is interesting to emphasize that the entity of surface markers expression did not significantly differ between HIV-DC and HD-DC in both untreated or treated conditions ([Figure 1A](#F1){ref-type="fig"}). Even if we observed lower viability in HIV-DC compared to HD-DC, this difference did not result statistically significant (*p* \> 0.999).

FLG induced the secretion of a good and similar amount of TNF in HD-DC and HIV-DC (*p* \< 0.05) ([Figure 1B](#F1){ref-type="fig"}). On the other hand, the production of IL-12 differs between HD-DC and HIV-DC (*p* = 0.029): while HD-DC produced significant level of IL-12 in response to the molecular pattern (FLG: 212.7 ± 53.1 pg/mL, vs. UN: 50.5 ± 2.9 pg/mL; *p* = 7 × 10^−4^), the induction of cytokine appeared to be less pronounced in HIV-DC (FLG: 63.9 ± 6.9 pg/mL, vs. UN: 38.2 ± 12.1 pg/mL; *p* \> 0.05) (Figure 1C).

Altogether these data indicate that FLG is able to activate HIV-DC in a similar way to that seen for HD-DC.

To test whether FLG-treated MDDC are able to induce a properly adaptive immunity response, a MDDC/lymphocytes co-culture assay was performed using autologous cells as previously described ([@B31], [@B32]). Lymphocytes alone were used as a negative control (Neg) ([Figures 1D,E](#F1){ref-type="fig"}).

A significant increment of IFN-γ^+^ CD4^+^ T cells was observed in healthy donors (FLG: 12.9 ± 5.5 % vs. UN: 1.3 ± 0.4 % positive cells; *p* = 0.022) as well as in HIV-infected individuals (FLG: 9.6 ± 1.8 % vs. UN: 0.1 ± 0.1 % positive cells; *p* = 0.014). Of note, the percentage of IFN-γ^+^ CD4^+^ T cells after FLG treatment was similar in healthy donor and patients (*p* \> 0.999). Negative control resulted similar to untreated co-cultures (*p* \> 0.05) ([Figure 1D](#F1){ref-type="fig"}), emphasizing that the increasing percentage of positive cells is not an artifact.

Moreover, FLG-treated MDDC were able to induce a significant proliferation of CD4^+^ T lymphocytes in healthy donors (FLG: 51.0 ± 12.1 %, vs. UN: 3.7 ± 0.9 % positive cells; *p* = 0.026) and patients (FLG: 24.3 ± 2.8 %, vs. UN: 3.5 ± 0.8 % positive cells; *p* = 0.038), even if in a lesser extent in patients compared to HD (*p* = 0.004). Negative control presented a proliferation rate similar to untreated co-cultures (*p* \> 0.05) ([Figure 1E](#F1){ref-type="fig"}).

It is interesting to underline that the limited percentage of positive cells in this type of assay is in accord with previously published data for autologous MDDC and T cells co-culture both in healthy donors ([@B32]) and even in HIV-infected patients ([@B31]) treated with unspecific stimuli (mitogens). Moreover, despite its limited entity, the activation of lymphocytes is consequence of MDDC stimulation as in the absence of MDDC (negative control) mitogens cannot activate T cells ([Figures 1D,E](#F1){ref-type="fig"}).

Taking in account the activation status of FLG-treated HIV-DC ([Figures 1A--C](#F1){ref-type="fig"}) together with their ability to induce lymphocytes activation ([Figures 1D,E](#F1){ref-type="fig"}), we clearly demonstrated that FLG is able to activate HIV-DC similarly to what observed for HD-DC. It is interesting to emphasize that, on the contrary, we have previously shown that HIV-DC did not properly respond to bacterial LPS ([@B14]).

Flagellin, but Not LPS, Induces Comparable Inflammasome Activation in MDDC From HIV-Infected Patients and Healthy Donors
------------------------------------------------------------------------------------------------------------------------

We then investigated the ability of flagellin to stimulate inflammasome in MDDC by the meaning of inflammasome cytokines production and caspase-1 activity. LPS alone or in combination with ATP was added to the assay as a positive control for inflammasome or NLRP3 inflammasome activation, respectively ([@B26]) ([Figure 2](#F2){ref-type="fig"}). A time-course assay treating MDDC with 5 μg/mL FLG or 1 μg/mL LPS was performed to determine the best experimental time for IL-1ß detection in this model, ([Supplementary File 6](#SM1){ref-type="supplementary-material"}), and selected 24 h for all the experiments.

![Flagellin induces better inflammasome activation in HIV-DC than LPS. 2 × 10^5^ MDDC from healthy donors (HD-DC; *n* = 20) or HIV-infected patients (HIV-DC; *n* = 20) were stimulated with 5 μg/mL flagellin (FLG) for 24 hours. 1 μg/mL LPS for 24 hours, or 1 μg/mL LPS for 24 hours plus 1 mM ATP for more 15 minutes were used as positive control for the activation of inflammasome and NLRP3 inflammasome, respectively. Culture supernatants were used to measure IL-1β **(A)** and IL-18 **(B)** concentration (pg/mL). Cells were harvested for analysis of caspase-1 activity by FAM-FLICA assay and flow cytometry. Percentage of FAM-FLICA+CD11c^+^ cells were reported for FLG-treated (FLG) and untreated (UN) MDDC **(C)**. Data are represented as mean ± standard error. Two-Way ANOVA test was applied to compare conditions within a group (HIV-DC or HD-DC; ^\*^*p* \< 0.05; LPS+ATP vs. LPS: ^\#^*p* \< 0.05) and between groups (HIV-DC vs. HD-DC; ^§^*p* \< 0.05).](fimmu-10-01291-g0002){#F2}

FLG induced a significant IL-1ß release in HD-DC (155.3 ± 20.7 pg/mL), compared to unstimulated cells (4.0 ± 1.9 pg/mL; *p* \< 0.0001) and similarly to LPS (132.4 ± 9.9 pg/mL; *p* \< 0.0001). The treatment with LPS+ATP resulted in a significant increase of IL-1ß release compared to LPS (*p* = 0.002), indicating a proper response of NLRP3 inflammasome in HD-DC ([Figure 2A](#F2){ref-type="fig"}).

In HIV-DC, the entity of IL-1ß production resulted lower than in HD-DC but significantly augmented compared to resting cells (FLG: 121.3 ± 34.3 pg/mL; vs. UN: 18.3 ± 9.3 pg/mL; *p* = 2 × 10^−4^) and also to LPS-treated cells (84.4 ± 17.5 pg/mL; *p* = 0.002). However, ATP did not alter LPS-induced IL-1ß production (*p* \> 0.05) ([Figure 2A](#F2){ref-type="fig"}), confirming the previously observed dysregulation of NLRP3 inflammasome in MDDC from HIV-infected patients ([@B14]).

In a similar way, FLG also induced significantly IL-18 release in HD-DC (FLG: 91.1 ± 19.3 pg/mL, vs. UN: 12.8 ± 6.1 pg/mL; *p* = 0.018) and at lower extent in HIV-DC (FLG: 50.5 ± 5.6 pg/mL, vs. UN: 2.9 ± 1.5 pg/mL; *p* = 0.009). HD-DC better respond to LPS and LPS+ATP than HIV-DC also in term of IL-18. There were no statistical differences in the production of IL-18 between HD- and HIV-DC ([Figure 2B](#F2){ref-type="fig"}).

Inflammasome cytokines release revealed that FLG is able to induce complex activation in MDDC from healthy as well as HIV-infected individuals. Accordingly, FLG increased caspase-1 activity in HD-DC (FLG: 6.8 ± 2.0 %, vs. UN: 0.3 ± 0.0 % positive cells) and in HIV-DC (FLG: 6.9 ± 0.7 %, vs. UN: 3.5 ± 0.5 % positive cells). HIV-DC presented a constitutively activated caspase-1, however a lower activation in response to LPS+ATP compared to HD-DC, once more emphasizing the specific dysregulation of NLRP3 pathway ([Figure 2C](#F2){ref-type="fig"}). Even if these differences did not reach statistical significance (*p* = 0.07), we underline that caspase-1 activity accompanies above-mentioned cytokines data, and that this is the first study showing a tendency in caspase-1 activation defect in MDDC from HIV-infected individuals. Although other studies have reported statistically significant differences in caspase-1 activity in healthy donors and HIV-infected patients, those results referred to lymphoid compartment or peripheral blood mononuclear cells, while little is known in myeloid cells ([@B37]--[@B40]).

Flagellin Induces Inflammasome Activation by Stimulated NAIP/NLRC4 and NLRP3 Receptors in HD-DC, but Not in HIV-DC
------------------------------------------------------------------------------------------------------------------

Once assessed that FLG is able to induce inflammasome activation in MDDC, we therefore tried to depict the pathways involved in complex formation and to detect any differences between HD-DC and HIV-DC.

Gene expression analysis revealed that HIV-DC presents a significant higher constitutive expression of *IL1B* and *IL18* compared to HD-DC. *NLRP3* also resulted increased even if not in a statistically significant way, while the level of *NAIP* and *NLRC4* was similar between MDDC ([Figure 3A](#F3){ref-type="fig"}).

![NLRC4 and NLRP3 are differentially involved in flagellin activation in HD-DC and HIV-DC. 2 × 10^5^ MDDC from healthy donors (HD-DC; *n* = 5) or HIV-infected patients (HIV-DC; *n* = 5) were stimulated with 5 μg/ml flagellin (FLG) for 3, 8, 18, and 24 hours. Cells were harvested for total RNA isolation and evaluation of relative gene expression by qPCR **(A--E)**. **(A)** Basal gene expression of *NLRP3, NAIP, NLRC4, CASP1, IL18*, and *IL1B* was expressed as 2^−Δ*Ct*^. **(B)** FLG-induced expression of *NLRP1, NLRP3, NLRC4, NAIP, CASP1, IL1B*, and *IL18* genes was calculated as 2^−ΔΔ*Ct*^ (fold-change, FC) and reported as logFC in a heat-map graph for HD-DC and HIV-DC. **(C)** FC values for *NLRC4* are compared between HD-DC and HIV-DC at all the time-points. **(D)** FC values for *NLRP3* are compared between HD-DC and HIV-DC at all the time-points. **(E)** Basal gene expression of *miR223, BRCC3, NEDD8*, and *CARD8* was expressed as 2^−Δ*Ct*^. **(F)** 2 × 10^5^ MDDC from healthy donors (HD-DC; *n* = 3) were pre-treated with 1,000 UI/mL of IFN-α-2b (Schering-Plough) for 18 h and then with 5 μg/ml flagellin (FLG) or LPS 1 μg/mL LPS for 24 hours, or 1 μg/mL LPS for 24 hours plus 1 mM ATP for more 15 minutes. IL-1ß concentration was measured in culture supernatants of HD-DC with and without IFN-α-2b pre-treatment and compared with HIV-DC (*n* = 3) stimulated with FLG. Data are represented as mean ± standard error. Multiple *t*-test was applied to compare HD- and HIV-DC in **(A,C--E)**. Kruskall-Wallis test was applied to compare HD-DC, HD-DC + IFN-α-2b, and HIV-DC sets in **(F)** (^\*^*p* \< 0.05).](fimmu-10-01291-g0003){#F3}

When the effect of flagellin was evaluated in genes modulation, we observed a revealed a different expression profile in HD-DC and HIV-DC at all the analyzed time-points (3, 8, 18, and 24 h) ([Figure 3B](#F3){ref-type="fig"}).

In particular, we focused our attention on the two receptors *NLRP3* and *NLRC4*. While, as expected, FLG induces NLRC4 gene modulation in HD-DC and HIV-DC ([Figure 3C](#F3){ref-type="fig"}), NLRP3 appeared to be defective in HIV-DC, as FLG was able to induce NLRP3 expression in HD, but not in HIV-DC ([Figure 3D](#F3){ref-type="fig"}), according to our previously published data ([@B14]).

The dysregulation observed for NLRP3 could be due to an imbalance of inhibitor and activator signals. NLRP3 is tightly regulated by endogenous proteins CARD8 ([@B41]), BRCC3 ([@B42]) and NEDD8 ([@B43]), and by miR-223 ([@B44]). Interestingly, the basal expression of *CARD8* and *BRCC3*, as well as of miR-223, resulted significantly augmented in HIV-DC compared to HD-DC ([Figure 3E](#F3){ref-type="fig"}), suggesting a possible cause of low responsiveness of NLRP3. Moreover, taking in account that IFN-I also contributes to the negative regulation of NLRP3 ([@B29], [@B30]) and that HIV-infected patients are known to present high level of circulating IFN-I ([@B45]--[@B47]), we shown that the treatment of HD-DC with IFN-a significantly reduced IL-1ß release specifically in LPS+ATP treated cells up to cytokine level observed in HIV-DC ([Figure 3F](#F3){ref-type="fig"}), emphasizing the inhibitory role of IFN-I on NLRP3 and suggesting that this could be another cause of a specific NLRP3 defect in HIV-DC.

According to our initial hypothesis, flagellin appears to be able to by-pass this defect of NLRP3 in HIV-DC, and at the same time our results have shown the involvement of both NLRC4 and NLRP3 receptors in HD-DC response to flagellin.

This hypothesis of a "two-receptors" mechanism is supported also by inflammasome "specks" detection through immunofluorescence staining of NLRP3 and NLRC4 ([Figure 4](#F4){ref-type="fig"}). NLRC4+ specks were evidenced in confocal imagines of FLG-treated HD-DC ([Figure 4A](#F4){ref-type="fig"}) and HIV-DC ([Figure 4B](#F4){ref-type="fig"}). NLRP3+ specks resulted more in FLG-treated HD-DC ([Figure 4A](#F4){ref-type="fig"}) than in HIV-DC ([Figure 4B](#F4){ref-type="fig"}). In general NLRC4 and NLRP3 staining localized in the same cells. By the use of CTCF index, we showed that FLG significantly induced both NLRC4+ and NLRP3+ specks in HD-DC (FLG vs. UN: *p* \< 0.0001) ([Figure 4C](#F4){ref-type="fig"}). On the other hands, in HIV-DC FLG induced preferentially NLRC4+ specks (CTCF FLG vs. UN: *p* = 0.0001) and at lesser extent NLRP3+ specks (*p* \> 0.05) ([Figure 4D](#F4){ref-type="fig"}). These findings demonstrated that in healthy donor cells, FLG not only activates inflammasome through the expected NAIP/NLRC4 pathway but also through the NLRP3 one.

![Flagellin induces NLRC4+ and NLRP3+ specks formation in MDDC. 2 × 10^5^ MDDC from healthy donors (HD-DC; *n* = 3) or HIV-infected patients (HIV-DC; *n* = 3) were cultured in 16-wells chamber slides and stimulated with 5 μg/mL FLG or 1 μg/mL LPS for 24 hours at 37°C 5% CO~2~ with or without 1 mM ATP for more 15 minutes. Mouse anti-human NLRP3 and rabbit anti-human NLRC4 antibodies and fluorescent secondary antibodies (Alexa 488-conjugated goat-anti-mouse IgG1; Alexa 647-conjugated goat-anti-rabbit IgG1) were used to label NLRP3+ and NLRC4+ specks, respectively. DAPI was used to counterstain nuclei. Images acquisition was performed using a DMi8 confocal laser scanning microscope. A representative experiment (magnification: 63x) was reported for HD-DC **(A)** and HIV-DC **(B)**. Arrows indicated NLRC4+ or NLRP3+ specks. **(C,D)** CTCF index for NLRP3+ and NLRC4+ specks in untreated (UN) and FLG-treated (FLG) MDDC. Data are represented as mean ± standard error. Mann-Whitney test was applied to compare UN and FLG conditions in **(C,D)** (^\*^*p* \< 0.05).](fimmu-10-01291-g0004){#F4}

To better investigate the involvement of NAIP/NLRC4 and NLRP3 in response to FLG in our model, we evaluated the IL-1ß production in FLG-treated MDDC previously incubated with 10 μM MCC-950, a specific NLRP3 inhibitor ([@B27]), or with 10 μM parthenolide/PTD, a large spectrum inflammasome inhibitor ([@B28]) ([Figures 5A,B](#F5){ref-type="fig"}).

![Flagellin significantly induces NLRC4 but not NLRP3 in HIV-DC. 2 × 10^5^ MDDC from healthy donors (HD-DC; *n* = 5) **(A)** and HIV-infected patients (HIV-DC; *n* = 5) **(B)** were pretreated with 10 μM MCC-950 or 10 μM parthenolide (PTD), and then stimulated with 5 μg/ml FLG for 24 hours or 1 μg/mL LPS for 24 hours with or without 1 mM ATP for more 15 minutes. IL-1ß concentration was measured in culture supernatants. 2 × 10^5^ MDDC from healthy donors (HD-DC; *n* = 3) **(C)** and HIV-infected patients (HIV-DC; *n* = 3) **(D)** were transduced with empty vector (scramble: Scr), shNLRC4 or shNLRP3, and then stimulated with 5 μg/ml FLG for 24 hours, or 1 μg/mL LPS for 24 hours with or without 1 mM ATP for more 15 minutes. IL-1ß concentration was measured in culture supernatants. Kruskal-Wallis test with multi comparison post-test was applied (treated vs. UN: ^\*^*p* \< 0.05; LPS+ATP vs. LPS ^\#^*p* \< 0.05; within each group: ^§^*p* \< 0.05; +MCC-950 vs. +PTD: ^\$^*p* \< 0.05; shNLRC4 vs. shNLRP3: £*p* \< 0.05; shNLRC4 vs. Scr: @*p*\<0.05).](fimmu-10-01291-g0005){#F5}

MCC-950 and PTD significantly inhibited IL-1ß production in FLG-treated HD-DC (78 and 90% of inhibition, respectively; *p* \< 0.05), as well as LPS+ATP-treated cells (78 and 90% of inhibition, respectively; *p* \< 0.05), and partially LPS-induced inflammasome activation (78 and 90% of inhibition, respectively; *p* \< 0.05) ([Figure 5A](#F5){ref-type="fig"}), due to the contribution of other pathway in inflammasome activation by LPS ([@B48]).

On the other side, MCC-950 was not able to significantly reduce cytokine release in HIV-DC stimulated with FLG (48% of inhibition; *p* \> 0.05), LPS (48% of inhibition; *p* \> 0.05) or LPS+ATP (48% of inhibition; *p* \> 0.05) ([Figure 5B](#F5){ref-type="fig"}). Accordingly, in the presence of MCC-950 a reduction not significantly of NLRP3+ specks was observed in HIV-DC ([Supplementary File 7](#SM1){ref-type="supplementary-material"}). PTD similarly inhibited IL-1β production in both FLG-treated HIV-DC (84% of inhibition *p* = 0.002), LPS or LPS+ATP-treated HIV-DC (84% of inhibition; *p* = 0.002), as expected due to the caspase-1 and NF-kB dependency for FLG-induced response ([@B49]), as well as for LPS-mediated one ([@B48]). These data confirm the greater involvement of NLRP3 in response to FLG in healthy donors compared to HIV-infected individuals.

Then we compared the differences in IL-1ß release in FLG-treated MDDC following *NLRC4* or *NLRP3* shRNA knockdown ([Figures 5C,D](#F5){ref-type="fig"}). In *NLRC4* shRNA-transduced MDDC, FLG induced a lower level of IL-1ß production compared to untreated cells both in HD-DC ([Figure 5C](#F5){ref-type="fig"}) and in HIV-DC ([Figure 5D](#F5){ref-type="fig"}). In *NLRP3* siRNA-transducted MDDC, FLG induced a lower level of IL-1ß compared to untreated cells in HD-DC ([Figure 5C](#F5){ref-type="fig"}), however this effect was not observed in HIV-DC ([Figure 5D](#F5){ref-type="fig"}). These data are in accord with above-reported effect of chemical NLRP3 inhibitor MCC-950 ([Figures 5A,B](#F5){ref-type="fig"}).

Altogether these findings allow us to suggest that FLG activates the inflammasome in human MDDC through the induction of NAIP/NLRC4 and NLRP3 receptors; the contribution of NLRP3 in FLG-signaling is less pronounced in HIV-DC due to the well-known "exhausted" profile of these cells ([@B50]).

Discussion {#s4}
==========

A number of microbial components have been proposed as alternative adjuvants to augment the immune responses of poorly immunogenic vaccines and/or of not fully immunocompetent individuals. Emerging evidence pointed out the possible use of bacterial flagellin in this context, firstly in mice \[as extensively revised in Hajam et al. ([@B17])\], but also in a human clinical trial of prophylactic vaccine ([@B23]). Studies in mice show the stimulatory capacity of flagellin to induce both humoral and cellular immune responses when implied together with pathogen\' antigens as adjuvant ([@B51], [@B52]) or in cancer immunotherapy ([@B53]).

Taking in account that, even in ART treatment, HIV-infected individuals continue to experience immune dysfunction, leading, among others side effects, to a deficient vaccine response ([@B9]), the necessity of new vaccine strategy in this population appear to be urgent.

Using the *in vitro* model of peripheral blood monocytes-derived-dendritic cells developed for HIV-infected patient\'s immunotherapy by Lu and collaborators ([@B54]), we demonstrated that flagellin is able to activate MDDC from HIV-infected patients as well as from healthy donors. Previous studies have evidenced the ability of flagellin to activate primary human monocytes, or human pro-monocytic cell line U38 ([@B55]), however here we demonstrated that flagellin is able to activate human MDDC considering both the MDDC profile as well as the MDDC-mediated lymphocytes activation ([Figure 1](#F1){ref-type="fig"}), with the exception of IL-12 production which results lower in HIV-DC compared to HD-DC, but in accord with previously published data ([@B56]).

Flagellin is sensed by two main innate immune receptors, TLR5 ([@B18]) and NAIP/NLRC4 ([@B57]--[@B59]). While it has been shown that flagellin induces NAIP/NLRC4 inflammasome activation in primary human macrophages and monocytes ([@B49], [@B60], [@B61]), little is known about its role in human DC. Despite it has been previously reported that flagellin stimulates IL-1β production in human MDDC ([@B62]), any evidence about NLRC4 or NLRP3 pathway in IL-1ß induction have been shown nor hypothesized. Besides the description of these two receptors within inflammasome activation by flagellin, our study also demonstrated for the first time the different contribution of the two receptors in HIV-DC response to flagellin.

As expected, flagellin induces the inflammasome activation through NAIP/NLRC4 both in HD-DC as well as HIV-DC ([Figure 2](#F2){ref-type="fig"}), suggesting that this pathway is still effective in HIV-infected patients, contrary to what seen for NLRP3 ([@B14]). Actually, HIV-DC presents a basal increased expression of NLRP3 inhibitory molecules, namely CARD8 ([@B41]), BRCC3 ([@B42]) and miR-223 ([@B44]), compatible with specific inhibition of this receptor ([Figure 3E](#F3){ref-type="fig"}).

While the low rate of NLRP3 response in HIV-DC has been attributed to the chronic inflammation of HIV-infected patients, consequent of HIV-1 persistence, endogenous viruses reactivation (i.e., herpes simplex virus), immune system exhaustion, increased intestinal permeability and microbial translocation (mainly LPS) and antiretroviral drugs cytotoxicity ([@B15], [@B63]) and taking in account that flagellate bacteria also could be present in gut microbiota, it remains obscure why the NAIP/NLRC4 pathway continues "ready-to-go." The administration of continues doses of LPS was found to be tolerogenic in mice ([@B64]), however any data are available about flagellin. We speculated that the increased IFN-a production in HIV-infected individuals (even if at lower levels in ART-treated patients) could be a possible cause of specific NLRP3 inhibition due to the known effect of the anti-viral mediator as NLRP3 negative regulators ([@B30]). It is important to underline that our cohort of ART-treated HIV-infected individuals presented a mean value of plasma IFN-a of about 50 pg/mL, 5-fold more than healthy individuals (about 10 pg/mL) (data not shown). Moreover, when HD-DC were treated with IFN-a their NLRP3 response is diminished similarly to what observed in HIV-DC ([Figure 3F](#F3){ref-type="fig"}), supporting our hypothesis. Another possible explication concerns the higher constitutive recruitment of adaptor molecule ASC (Apoptosis speck like with a CARD) in inflammasome complex in HIV-infected patients compared to healthy controls as recently observed by Ahmad and colleagues ([@B65]) in PBMC. In this case, inflammasome receptors, which need ASC to mount the complex (i.e., NLRP3), could be disadvantaged in respect to sensors that directly recruit caspase-1, such as NLRC4.

Beyond the main purpose of this article, and for the first time to our knowledge, we demonstrated that NLRP3 also contribute to flagellin response in human MDDC, as revealed by NLRP3+ specks formation in FLG-treated cells ([Figure 4](#F4){ref-type="fig"}) and by specific (chemical and genetic) inhibition of this receptor ([Figure 5](#F5){ref-type="fig"}). Our findings are in lines with previous reports about NLRC4 and NLRP3 co-localization into a unique complex in HEK293 cells ([@B66]) and in mice bone marrow-derived macrophages during *Salmonella* infection ([@B67]).

Therefore, flagellin induces the two pathways in HD-DC, whereas it preferentially activates NLRC4 pathway in HIV-DC due to the defect in NLRP3 in these cells. Despite the immunofluorescence visualization of both NLRP3+ and NLRC4+ specks, our data are not sufficient to determine whether the two receptors are truly co-localized in the same inflammasome complex, and further investigations will be needed to finally prove it.

In conclusion, our data support the use of flagellin in the design of future vaccines effective also in immunocompromised individuals, such as HIV-infected patients. According to our findings, flagellin activates human MDDC from healthy and HIV-infected individuals through the NAIP/NLRC4 inflammasome, with the participation of NLRP3 at least in healthy donors cells. Flagellin was able to by-pass the NLRP3 defect in HIV-DC, contributing to inflammasome activation and consequently full MDDC maturation in HIV-infected patients.
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